Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.